In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|August 28, 2026
ACT Brief: Site Relationships and Payment Reliability, AI Adoption Without Governance Risk, and China's Biotech Innovation Rise
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how unpredictable payments damage site retention, why rapid AI deployment without validation creates regulatory risk, and China's growing dominance in early-stage drug discovery.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part four of his interview , Patrick Mizer, chief technology officer at Ledger Run, explains how unpredictable payments erode site relationships over time. Operational excellence in payments is becoming increasingly important to landing and retaining the best investigative sites, shifting payment infrastructure from a back-office commodity into a competitive differentiator in site competition. - In a
new contributed article , Philip Raeth examined how AI is reshaping clinical research faster than any technology before it, but adoption without GxP-grade governance, validation, and human oversight is not strategy, it is risk. The regulatory expectation that human decision-makers maintain responsibility for outcomes remains regardless of how quickly new models arrive or how compelling their performance appears. - In a
new Q&A from Pharmaceutical Executive , Dr. Ying Huang, CEO of K2 Therapeutics, discussed why China's biotech ecosystem is driving innovation at scale, with licensing commitments reaching $51.9 billion in 2024, a 90% jump from 2023. Public investment in basic science across Asia is translating into industrial R&D productivity, creating an entrepreneurial ecosystem of approximately three to four thousand biotech companies that Western pharma is now accessing through global asset acquisition.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
5